Only the “NT-type” GMB showed an enhanced mGlu3 and mGlu5 receptor expression with respect to low-grade gliomas, and, therefore, the two receptors cannot be considered as biochemical markers of GBM with respect to other types of gliomas but may facilitate the identification of a specific GBM subgroup. Here, GRM3 is linked to central nervous system cancer.